An anonymous director reports

MEDIPHARM LABS SETS DATE TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS

Medipharm Labs Corp. will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, Aug. 14, 2024.

Medipharm Labs executive management team will also host a conference call and audio webcast on Wednesday, Aug. 14, 2024, at 8:30 a.m. Eastern Time, to discuss the company's financial results.

Audio conference call dial-in details

Toll-free in North America:  888-330-2454

International toll:  1-240-789-2714

Conference ID No.:  4921762

Participants are asked to dial in approximately 15 minutes before the start of the call.

Audio webcast:  An audio webcast will be available.

For those who are unable to participate on the live conference call or webcast, a replay will be available on the company's website approximately one day after completion of the call.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a GMP-certified (good manufacturing practices) facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic GMP licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the U.S. Food and Drug Administration (FDA).

In 2023, Medipharm acquired Vivo Cannabis Inc., which expanded Medipharm's reach to medical patients in Canada via the Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

We seek Safe Harbor.